This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Farber syndrome (lipogranulomatosis)Farber Disease (Farber Lipogranulomatosis)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E75.2 | Special Copayment Reduction: V117 | Special Copayment Reduction period: 5 years
B. SynonymsFarber lipogranulomatosis, Acid Ceramidase Deficiency, ceramidase deficiency, Ceramidosis
C. Adult onsetFirst onset in adulthood unlikely — symptoms mostly begin in infancy (within the first few months of life), and survival into adulthood is very rare.
1. HistoryFirst described by Sidney Farber in 1952, enzyme deficiency confirmed in 1972, ASAH1 gene identified in the 1990s
2. CausesASAH1 gene mutations cause lysosomal acid ceramidase deficiency → ceramide accumulation in tissues
3. GeneticsAutosomal recessive, ASAH1 (8p22), more than 50 pathogenic variants reported
4. EpidemiologyVery rare, fewer than 200 cases reported worldwide, no particular ethnic concentration
5. PathophysiologyLysosomal accumulation of ceramide, induction of apoptosis, granuloma formation
6. SymptomsThree cardinal signs of joint pain and swelling, subcutaneous nodules and hoarse voice, plus neurological deterioration
7. SignsMultiple joint deformities, lipogranulomatous nodules, hepatosplenomegaly, white matter abnormalities on MRI
8. ScreeningEnzyme activity measurement on dried blood spots (DBS), plasma ceramide analysis
9. DiagnosisConfirmation of reduced enzyme activity in leukocytes/skin fibroblasts + ASAH1 gene analysis
10. TreatmentHematopoietic stem cell transplantation (HSCT) — improves non-neurological symptoms; gene therapy research under way
11. PrognosisSevere forms die before age 2; mild forms can survive into adolescence
12. PreventionGenetic testing, preimplantation genetic diagnosis (PGT), genetic counseling
13. ReferencesAlayoubi AM et al. Systemic ceramide accumulation leads to severe and varied pathological consequences and 9 other papers

1. History

Farber disease became known in 1952 when the American pediatrician Sidney Farber first described 2 infant patients with joint pain, subcutaneous nodules and a hoarse voice. In the pathological findings of this disease, Farber identified granulomatous lesions in which fatty material was deposited in periarticular tissues and visceral organs, and named it 'lipogranulomatosis.' At the time, the exact nature of the metabolic abnormality had not been revealed, but subsequent research made it clear that the cause is an abnormality of lysosomal lipid metabolism.

In 1972, Sugita and colleagues first demonstrated that ceramide is abnormally accumulated in the tissues of patients with Farber disease, and in the same year Moser and colleagues confirmed that the activity of the lysosomal enzyme acid ceramidase (N-acylsphingosine amidohydrolase) is markedly reduced. This provided the biochemical basis for classifying Farber disease as a type of lysosomal storage disease.

In the 1990s, with advances in molecular biological techniques, the ASAH1 gene was identified, and pathogenic variants in this gene were shown to cause acid ceramidase deficiency. Koch and colleagues (1996) succeeded in cloning the ASAH1 gene, and various mutation types subsequently began to be reported. Since the 2000s, pathophysiology research and development of treatment strategies using animal models have been actively pursued, and cases of clinical improvement through hematopoietic stem cell transplantation have accumulated. In 2018, Dworski and colleagues reported that hematopoietic stem cell transplantation brings about biochemical and functional correction in an acid ceramidase-deficient mouse model, and research is currently under way toward the clinical application of gene therapy and enzyme replacement therapy.

2. Causes

The fundamental cause of Farber disease is functional deficiency of the lysosomal acid ceramidase (AC) enzyme due to pathogenic variants of the ASAH1 gene. Acid ceramidase is an enzyme responsible for a key step of sphingolipid metabolism within the lysosome, catalyzing the hydrolysis of ceramide into sphingosine and fatty acid. Deficiency of this enzyme blocks the lysosomal ceramide degradation pathway, and undegraded ceramide progressively accumulates within cells.

Ceramide is a core component of sphingolipids and an important lipid molecule involved in cell signaling, apoptosis and maintenance of cell membrane structure. Ceramide, normally generated as the final product during the degradation of several sphingolipids in the lysosome, must be converted to sphingosine by acid ceramidase. Reduction or loss of enzyme activity due to ASAH1 gene mutations blocks this degradation pathway, causing ceramide to accumulate in tissues throughout the body, such as skin, joints, visceral organs and the nervous system. Abnormal accumulation of ceramide is understood to disrupt cellular homeostasis and induce chronic inflammatory responses and granuloma formation. Ceramide is also a potent apoptosis-inducing molecule, and its accumulation can promote apoptosis in various cell types, including neurons.

3. Genetics

Farber disease is inherited in an autosomal recessive manner. The causative gene, ASAH1, is located on chromosome 8p22, consists of 14 exons and encodes the precursor protein of acid ceramidase (prepro-ceramidase). The precursor protein is processed in the endoplasmic reticulum and transported to the lysosome, where, in the acidic environment, it is cleaved into α and β subunits that form the active heterodimer.

More than 50 pathogenic ASAH1 variants have been reported to date, with various variant types identified, including missense, nonsense, splice site variants and small deletions/insertions. Studies of genotype-phenotype correlation indicate that the degree of residual enzyme activity correlates to some extent with clinical severity. When there is almost no residual enzyme activity, an early-onset form with severe nervous system involvement tends to appear, and when some residual enzyme activity remains, a phenotype with mild or no nervous system involvement tends to appear. Representative pathogenic variants reported include p.Tyr36Cys and p.Pro362Arg, and some variants are associated with the spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) phenotype, whose clinical picture differs from Farber disease. Heterozygous carriers show no clinical symptoms, but enzyme activity can be confirmed to be about 50% of normal.

4. General epidemiology

Farber disease is a very rare lysosomal storage disease worldwide, with fewer than 200 cases estimated to have been reported in the literature to date. Statistics on the exact prevalence or incidence are not well established, but it is estimated to occur at a frequency of less than 1 per roughly 1:100,000–1:1,000,000 newborn births. No tendency to concentrate in particular geographic regions or ethnic groups has been reported to date, and it is known to occur sporadically among various ethnic groups worldwide. There is no difference in frequency between males and females.

Because diagnosis is very difficult and clinical awareness is low, the actual number of patients is likely much higher than reported. Infants presenting with joint pain as the chief complaint are often misdiagnosed with rheumatoid arthritis or infectious arthritis, so the actual prevalence of Farber disease is likely underestimated. A small number of cases have also been reported in Korea, but accurate epidemiological data are lacking. It is a disease requiring systematic data collection through rare disease registries.

5. Pathophysiology

The pathogenesis of Farber disease begins with loss of lysosomal acid ceramidase activity due to ASAH1 gene mutations. Acid ceramidase catalyzes the hydrolysis of ceramide into sphingosine and fatty acid in the acidic environment of the lysosome (pH 4.5–5.0), and when the activity of this enzyme is deficient, ceramide progressively accumulates in the lysosome. In particular, because ceramide is produced at the final step of the lysosomal degradation pathways of several sphingolipids, such as glucocerebroside, galactocerebroside and sphingomyelin, acid ceramidase deficiency creates a bottleneck in the metabolism of various sphingolipids.

Accumulated ceramide has wide-ranging effects on intracellular signaling pathways. Ceramide is known as a potent inducer of apoptosis and activates apoptotic pathways to promote the death of various cell types, including neurons. Ceramide accumulation also induces chronic inflammatory responses, and as macrophages and monocytes in the tissues phagocytose lipids, characteristic lipogranulomas form. These granulomas form in various tissues, such as joint capsules, subcutaneous tissue, larynx, liver, spleen, lungs and heart. In the nervous system, neuronal death, glial cell activation and myelin damage due to accumulated ceramide progress together, causing neurological deterioration.

6. Symptoms

The classic clinical triad of Farber disease is ① painful joint swelling and deformity, ② subcutaneous lipogranulomatous nodules, and ③ hoarse voice (hoarseness) or a weak, hoarse cry. In most patients, symptoms begin within 2–6 months of birth, and initially extreme irritability and fever are often seen.

Joint symptoms are prominent from the outset, with pain, swelling and restricted motion across multiple joints such as the wrists, ankles, knees and thumbs. As the disease progresses, joint deformities become fixed and flexion contractures form. Subcutaneous nodules arise mainly in areas where skin and bone are close together, such as the tibial crest, around joints and the occiput, appearing as firm, painless nodules a few mm to several cm in size. Hoarseness due to laryngeal involvement is an important diagnostic clue. The degree of nervous system involvement varies greatly with phenotype, and in severe forms developmental delay, developmental regression, hypotonia and seizures appear. Hepatosplenomegaly, respiratory distress and pulmonary infiltrates may also be observed. The clinical forms of Farber disease are broadly classified into 7 subtypes (subtype 1–7), and subtype 1 is the most common classic severe form with nervous system involvement.

7. Signs

On physical examination, swelling, warmth and restricted motion of multiple joints and periarticular subcutaneous nodules are characteristic. The nodules are yellow to brown, and their consistency varies but is generally firm. Laryngoscopy may show vocal cord nodules or vocal cord edema. In severe cases, airway obstruction can result, so caution is needed. Hepatosplenomegaly can be confirmed by abdominal palpation, and its exact size is assessed by imaging.

On imaging, plain radiographs may show soft tissue swelling, periarticular calcification and bone erosions. MRI is useful for assessing soft tissue changes in and around joints and bone marrow involvement. Brain MRI may show white matter signal abnormalities, cerebellar atrophy and brainstem abnormalities, reflecting the degree of nervous system involvement. Biochemically, acid ceramidase enzyme activity in leukocytes or skin fibroblasts is markedly reduced to less than 6% of normal, and ceramide species are abnormally increased in plasma and tissues. Histopathologic examination of skin nodules shows granulomas mixed with giant cells and histiocytes, intracellular lipid vacuole formation, and a characteristic electron microscopic finding called Farber bodies.

8. Screening

A systematic newborn screening program for Farber disease has not been established in most countries at present. This is because of the very low incidence of the disease and insufficient development of sensitive and specific biomarkers usable for newborn screening. However, the possibility of measuring acid ceramidase activity is being explored in the development of expanded newborn screening panels including multiplex enzyme assays for lysosomal storage diseases.

When Farber disease is clinically suspected, measurement of acid ceramidase enzyme activity using dried blood spots (DBS) or leukocytes is used as an initial screening test. Enzyme activity assays using fluorescent substrates have been established, and in patients activity is reduced to less than 5% of normal. Recently, analysis of ceramide and related metabolites through plasma sphingolipid profiling has attracted attention as a sensitive biomarker. Mass spectrometry-based quantitative ceramide analysis can be usefully applied to the biochemical diagnosis of Farber disease and monitoring of treatment. When there is a family history, carrier diagnosis through molecular genetic testing is important, making preimplantation genetic diagnosis or prenatal diagnosis possible.

9. Diagnosis

Confirmation of Farber disease is based on two pillars: ① biochemical testing and ② molecular genetic testing. Biochemical confirmation is demonstrating that acid ceramidase enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts is less than 10% (usually less than 6%) of normal controls. This is performed by fluorometric assay using fluorescent substrates or by tests using radioisotope-labeled substrates. Molecular genetic confirmation is identifying pathogenic variants in both alleles (biallelic) of the ASAH1 gene, carried out through next-generation sequencing (NGS) panel testing or whole-exome sequencing (WES).

Farber disease is clinically suspected when ① multiple joint pain and swelling beginning in infancy, ② subcutaneous nodules and ③ hoarse voice appear in combination. The differential diagnosis includes juvenile idiopathic arthritis, other lysosomal storage diseases (Niemann-Pick disease, Gaucher disease) and other disorders that cause multiple subcutaneous nodules. Tissue biopsy (skin nodules, lymph nodes, etc.) is useful for confirming characteristic lipogranuloma findings and Farber bodies on electron microscopy, and provides evidence supporting the diagnosis. Prenatal diagnosis is possible by enzyme activity measurement and molecular genetic testing on amniocytes or chorionic villus sampling (CVS) specimens.

10. Treatment

There is currently no curative treatment for Farber disease, and hematopoietic stem cell transplantation (HSCT) is recognized as the most effective treatment for non-neurological symptoms. HSCT works on the principle of transplanting hematopoietic stem cells derived from a normal donor, with the transplanted cells supplying acid ceramidase. According to clinical experience, improvement of hoarseness, reduction of subcutaneous nodules and relief of joint pain have been seen in patients with Farber disease who received HSCT. However, HSCT has the limitation of not crossing the blood-brain barrier (BBB), so its effect in suppressing neurological progression is limited in patients with severe nervous system involvement.

Symptomatic treatment includes management of joint pain and inflammation with nonsteroidal anti-inflammatory drugs and steroids, maintenance of joint function through physical and occupational therapy, anticonvulsants for seizure control, and nutritional support. When respiratory function is impaired, endotracheal intubation or tracheostomy may be needed. A recent study reported that an approach combining anti-inflammatory treatment with tocilizumab (IL-6 receptor blocker) and HSCT was effective in some patients (Furujo et al., 2025). Research on developing recombinant acid ceramidase for enzyme replacement therapy (ERT) is also under way, and an ASAH1 gene correction approach using AAV vectors as gene therapy is being studied at the preclinical stage. A strategy of inhibiting ceramide biosynthesis as substrate reduction therapy is also theoretically possible but has not yet reached the stage of clinical application.

11. Prognosis

The prognosis of Farber disease varies greatly depending on the clinical subtype and the degree of nervous system involvement. In the classic severe form (subtype 1), neurological deterioration progresses rapidly, and most patients die of respiratory failure or severe infection before age 2. In mild forms with little or no nervous system involvement (subtypes 3, 5), patients may survive into adolescence or adulthood, but quality of life is greatly reduced by the gradual worsening of joint deformities and pain.

In patients who received HSCT, significant improvement in non-neurological symptoms (joint pain, subcutaneous nodules, hoarse voice) is observed, and there are reports that survival is extended when transplantation is completed successfully without transplant-related complications. However, neurological complications may continue to progress even after transplantation, and the benefit of HSCT is limited in patients with severe nervous system involvement. Long-term prognostic data are lacking because of the extremely low incidence of the disease, and natural history studies through multicenter registries are needed.

12. Prevention

Because Farber disease is an autosomal recessive genetic disease, when both parents are heterozygous carriers of a pathogenic ASAH1 gene variant, an affected child may be born with a 25% probability in each pregnancy. Therefore, genetic counseling is essential when there is a family history or for couples who have already had an affected child. When both parents are confirmed as carriers by molecular genetic testing, prenatal diagnosis is possible in subsequent pregnancies.

Prenatal diagnosis is performed by acid ceramidase enzyme activity measurement or ASAH1 gene analysis on specimens obtained by chorionic villus sampling (CVS) at 10–12 weeks of gestation or amniocentesis at 16–18 weeks of gestation. Preimplantation genetic testing (PGT) is a method of selecting and transferring embryos without the pathogenic variant from among embryos obtained by in vitro fertilization in carrier couples, and can prevent the birth of a child with Farber disease. It is also important to perform carrier testing in family members of patients with confirmed Farber disease, and stepwise genetic testing of parents, siblings and relatives (cascade genetic testing) is recommended.

13. References

  1. Farber S, Cohen J, Uzman LL. Lipogranulomatosis: A new lipo-glycoprotein "storage" disease. J Mt Sinai Hosp N Y. 1957;24(6):816-837. PMID: 13481308
  2. Moser HW, Prensky AL, Wolfe HJ, Rosman NP. Farber's lipogranulomatosis: Report of a case and demonstration of an excess of free ceramide and ganglioside. Am J Med. 1969;47(6):869-890. PMID: 5350218
  3. Koch J, Gärtner S, Li CM, et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of The First Molecular Lesion Causing Farber Disease. J Biol Chem. 1996;271(51):33110-33115. PMID: 8955159
  4. Levade T, Sandhoff K, Schulze H, Medin JA. Ceramide metabolism and Farber disease. In: Scriver CR, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001. DOI:10.1036/ommbid.116
  5. Alayoubi AM, Wang JC, Au BC, et al. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med. 2013;5(6):827-842. PMID: 23681698
  6. Dworski S, Lu P, Khan A, et al. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):386-394. PMID: 27890679
  7. Ehlert K, Frosch M, Fehse N, et al. Farber disease: Clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J. 2007;5:15. PMID: 17603883
  8. Solyom A, Medin JA. Acid ceramidase deficiency: Farber disease and SMA-PME. In: Adam MP, et al., eds. GeneReviews® [Internet]. University of Washington, Seattle; 2018. PMID: 30029679
  9. Yeager AM, Uhas KA, Coles CD, et al. Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant. 2000;26(3):357-363. PMID: 10967581
  10. Furujo M, Kosuga M, Okuyama T. Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long-Term Outcome. JIMD Rep. 2025;66(4). DOI:10.1002/jmd2.12481